Login to Your Account



Cstone to start clinical trials of breakthrough cancer drug

By Carmen Ho
Staff Writer

Tuesday, July 18, 2017

HONG KONG – Cstone Pharmaceuticals Co. Ltd. has received the go-ahead from the CFDA to conduct clinical trials with its investigational agent, CS-1001, making it the first company in China to successfully have a fully human, full-length anti-PD-L1 monoclonal antibody enter clinical development.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription